Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)28.41m
- Net income in EUR-19.95m
- Incorporated2002
- Employees145.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai OPM Biosciences Co Ltd | 43.04m | 5.27m | 775.94m | 328.00 | 149.02 | 3.02 | -- | 18.03 | 0.3751 | 0.3751 | 3.18 | 18.51 | 0.1558 | 2.50 | 4.05 | 1,075,953.00 | 1.88 | 3.50 | 1.96 | 3.69 | 50.40 | 57.44 | 12.09 | 21.40 | 15.47 | -- | 0.0272 | 58.30 | 22.26 | 38.41 | -61.04 | -- | 43.46 | -- |
| Kexing Biopharm Co Ltd | 184.92m | 15.31m | 777.07m | 947.00 | 50.35 | 3.66 | -- | 4.20 | 0.6288 | 0.6288 | 7.47 | 8.65 | 0.473 | 4.20 | 2.90 | 1,601,171.00 | 3.82 | -0.1893 | 5.31 | -0.2413 | 63.12 | 74.57 | 8.07 | -0.3956 | 1.38 | 63.54 | 0.4489 | -- | 11.75 | 3.39 | 116.54 | -27.74 | 11.90 | -- |
| Industri Jamu dn Frms Sd Mncl Tbk PT | 201.78m | 60.79m | 790.29m | 3.56k | 12.92 | 4.54 | 11.90 | 3.92 | 40.62 | 40.62 | 134.92 | 115.65 | 1.05 | 3.17 | 5.99 | 1,128,331,000.00 | 31.51 | 27.62 | 33.97 | 31.69 | 58.69 | 56.70 | 30.13 | 28.98 | 5.29 | -- | 0.0005 | 97.08 | 9.90 | 5.02 | 23.18 | 7.71 | -19.12 | 9.91 |
| Medincell SA | 28.41m | -19.95m | 792.30m | 145.00 | -- | -- | -- | 27.89 | -0.6143 | -0.6143 | 0.8982 | -0.9254 | 0.4258 | -- | 28.18 | 202,907.10 | -29.90 | -51.18 | -50.21 | -133.26 | 56.60 | 82.68 | -70.22 | -210.68 | -- | -0.9935 | 2.11 | -- | 181.43 | 54.88 | 26.36 | -- | 13.30 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 185.08m | 55.82m | 803.26m | 789.00 | 14.39 | 1.84 | 11.81 | 4.34 | 0.6157 | 0.6157 | 2.04 | 4.81 | 0.3878 | 0.4134 | 4.92 | 2,185,246.00 | 12.14 | 15.34 | 13.34 | 17.17 | 63.00 | 68.94 | 31.29 | 39.16 | 11.43 | -- | 0.0327 | 52.52 | 5.69 | 2.38 | -7.42 | -2.09 | 20.50 | 8.76 |
| Procter & Gamble Health Ltd | 119.98m | 28.66m | 804.72m | 1.33k | 28.11 | 13.90 | 26.17 | 6.71 | 184.66 | 184.66 | 772.89 | 373.35 | -- | -- | -- | 9,686,425.00 | -- | -- | -- | -- | 73.77 | -- | 23.89 | -- | 2.30 | 754.85 | 0.0099 | -- | -- | -- | -- | -- | -- | -- |
| CStone Pharmaceuticals | 24.70m | -46.00m | 812.07m | 93.00 | -- | 19.54 | -- | 32.88 | -0.3259 | -0.3259 | 0.176 | 0.26 | 0.1487 | 1.38 | 1.68 | 1,689,365.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| Genomma Lab Internacional SAB de CV | 891.68m | 84.07m | 812.69m | 1.71k | 9.86 | 1.49 | 7.82 | 0.9114 | 1.71 | 1.15 | 18.06 | 11.27 | 0.7721 | 3.09 | 3.71 | 11,333,190.00 | 7.28 | 6.85 | 10.26 | 10.26 | 63.30 | 61.94 | 9.43 | 8.93 | 1.54 | 3.88 | 0.4025 | 24.81 | 12.99 | 7.92 | 92.74 | 22.77 | 1.53 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 30 Jun 2025 | 2.46m | 7.37% |
| Polar Capital LLPas of 22 Jan 2026 | 1.67m | 5.01% |
| Adage Capital Management LPas of 30 Jun 2025 | 1.26m | 3.78% |
| Syquant Capital SASas of 30 Jun 2025 | 923.76k | 2.77% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 755.32k | 2.27% |
| CPR Asset Management SAas of 31 Dec 2025 | 554.14k | 1.66% |
| AXA Investment Managers (Paris) SAas of 30 Jan 2026 | 363.21k | 1.09% |
| Saint Olive Gestion SNCas of 31 Dec 2025 | 339.05k | 1.02% |
| Amundi Asset Management SASU (Investment Management)as of 31 Dec 2025 | 335.30k | 1.01% |
| Montpensier Arbevel SASas of 30 Jun 2025 | 298.30k | 0.90% |
